Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval
By Ben Glickman
Pharmaceutical regulators approved Amgen's Bkemv, a biosimilar to rare-disease treatment Soliris.
The Food and Drug Administration said Tuesday that Bkemv, a monoclonal antibody, had been approved for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder, and atypical hemolytic uremic syndrome, another rare disease affecting kidneys and blood-clotting.
Soliris, developed by AstraZeneca-owned Alexion Pharmaceuticals, is approved for the same treatment indications.
In patients with paroxysmal nocturnal hemoglobinuria, Bkemv is given to reduce hemolysis, while in treating atypical hemolytic uremic syndrome, the drug inhibits complement-mediated thrombotic microangiopathy.
The FDA said that Bkemv was the first interchangeable biosimilar to Soliris to treat the diseases.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 28, 2024 18:40 ET (22:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks